Editor’s note: The opinions of the smart, well-read women in my Denver book club mean a lot, and often determine what the rest of us choose to pile onto our bedside tables. So we asked them, and all ...
Humana faces industry headwinds with Medicare Advantage pressures, but management maintains 2025 earnings guidance and steady operational performance. HUM stock trades at a discount to peers, ...
Humana's stock has declined 18% while the S&P 500 returned 13.5%, driven by short-term issues with Medicare Advantage. Despite short-term cost challenges, Medicare Advantage remains a long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results